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Abstract 
The purpose of this paper is to assess the extent to which modeled or simulated cost-effectiveness claims published in Value in Health 
in  2015 meet the standards of normal science. To meet these standards, modeled or simulated claims must be credible. They must be 
capable of empirical evaluation and replication. If these standards are not met then such claims run the risk of being labeled as 
pseudoscience. Following a systematic review of all publications in Value in Health, 16 papers were identified. Of these 14 presented 
a cost-per-QALY analysis, with 9 presenting their claims for comparative effectiveness in a lifetime cost-per-QALY framework. With 
the focus of the assessment on whether or not these studies generated testable claims, none of the studies met this standard. They 
were best seen as thought experiments or imaginary worlds. Recipients of such claims can of course, on the one hand, reject them 
outright as not meeting accepted standards in normal science. After all, QALYs are never collected by health care systems and are 
unlikely to be collected. This means that the outcome metrics are untestable and may never have been intended to be tested. On the 
other hand, if the recipient believes that the model or simulation provides a sufficient correspondence to reality then the claims made 
are necessarily entailed. The issue of testing is irrelevant to the belief in the credibility of the claims. The modeled or simulated claims 
are immune to failure. The review concluded that none of the claims presented were in a testable form and that while 7 (at most) of 
the studies had the potential to generate testable claims, the rest were immune to failure. In the absence of testable claims, the 
studies reviewed are most appropriately characterized as imaginary worlds or thought experiments. 
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Introduction 
In a recent supplement to the Journal of Medical Economics 
(JME), the case was put forward that if claims for the impact 
of products and devices on costs and outcomes in health care 
systems are to be accepted then they should meet the 
standards expected in ‘normal science’ 1  2 3 4. The argument 
was made that if modeled or simulated claims are to be 
credible, practical and useful in formulary decisions then the 
only acceptable claims are those that are potentially 
falsifiable and replicable in a timeframe relevant to the needs 
of a formulary committee. If claims do not meet this standard 
they should be rejected. 
 
The present review of cost-effectiveness studies published in 
Value in Health in the period January 2015 to December 2015 
follows from two previous assessment of modeled or 
simulated cost-effectiveness studies published in 
PharmacoEconomics (PECON) and the JME in the same time 
period 5 6 . Both reviews concluded that the majority of  
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studies published did not meet the standards of normal 
science. The studies were best characterized as thought 
experiments or imaginary worlds; as pseudoscience rather 
than science in putting to one side the construction of 
empirically evaluable theories and hypotheses. This is 
exemplified in the choice of cost-per-QALY endpoints. Apart 
from the fact that there is no accepted standard for a QALY 
metric, this is an immediate barrier to generating testable 
hypotheses as QALYs are not only not collected by health 
systems but no health system appears to be interested in 
collecting them 7.  
 
With the exception of a handful of single payer health care 
systems that have embraced the National Institute for Health 
and Care Excellence (NICE) reference case, to include New 
Zealand (with the exceptions of cost-per-QALY thresholds) 
and Ireland, there seems little interest in adopting the 
reference case constructed model or simulation format to 
support pharmaceutical product decisions 8 9 10 11. Mention 
should, however, be made of the Academy of Managed Care 
Pharmacy (AMCP) Format for Formulary Submissions in the 
US, which recommends long-term models and simulations in 
chronic disease 12. This Format, unfortunately, also fails to 
meet the standards of normal science 13. 
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Methods 
A systematic review, following the PRISMA-P checklist (MeSH 
terms ‘cost’, ‘cost effectiveness’ , ‘QALY’) of all papers 
published in Value in Health in the period January 2015 to 
December 2015, identified 16 economic evaluation studies 14. 
In order to judge whether the modeled claims presented met 
the standards of normal science four questions were 
considered: 
 
• Is the model capable of generating testable claims? 
• Did the author(s) attempt to generate testable 
claims? 
• Did the author(s) suggest how the claims might be 
evaluated? 
• Did the author(s) caution readers as to the 
implications of generating non-testable claims? 
Each author independently reviewed the selected studies 
with consensus agreement reached on the assessment. 
A testable claim was defined as one that could be evaluated 
empirically in a timeframe relevant to the needs of a 
formulary committee (ideally a period of  up to 2 to 3 years). 
This period was chosen because a testable claim was seen as 
provisional. A product or device could, in this context, be 
accepted by a formulary committee for formulary listing, but 
subject to an agreement with the manufacturer to report 
back to the committee with evidence to support the claims 
made. These claims could be for product comparative 
effectiveness, for the impact of the product on resource 
utilization or some combination of these to support a claim 
for incremental cost-effectiveness. The claim for comparative 
effectiveness could encompass clinical endpoints as well as 
those captured as patient reported outcomes.   
 
In judging whether or not a model might support testable 
(falsifiable) claims, even if the possibility was not considered 
by the author(s), three characteristics of the model are 
important. These are (i) the modeling framework, (ii) the 
choice of primary outcome measure; and (iii) the time frame 
for the model.  A Markov or discreet event simulation model 
with a lifetime perspective and with discounted cost per 
QALY claims as the primary endpoints would be one that 
would be impossible to evaluate. There is no chance of 
falsification, feedback to decision makers or replication.  It 
would be assessed as immune to failure. Against this, a 
simple, trial-based decision model with a timeframe of 12 to 
18 months with claims expressed in clinical (including PROs) 
and resource utilization endpoints would, given access to 
readily available data sources in the US, be open to 
hypothesis testing and feedback to a formulary committee. 
 
The important point to note is that the modeled claim was 
not to be judged on the reasonableness or otherwise of the 
assumptions of the model. Certainly the model would be 
expected to cover comparator products, or least the key 
comparators, and to identify the target population for the 
claims. Beyond this, there was no attempt to evaluate 
whether or not the model necessarily complied with ISPOR 
recommended standards for good practice, although given 
that Value in Health subscribes to these standards, notably 
the CHEERS format, it was assumed that these criteria would 
have been addressed as part of the peer review process 15.  
 
Results  
Table 1 summarizes the results of the review of the economic 
evaluation studies. Each paper is assessed under four 
headings: 
 
• Target population and intervention (product, 
comparator products, devices) 
• Sponsor (financial support if known) 
• Modeling technique and major claims (simple 
decision model, Markov or cohort model, discrete 
event simulation) 
• Claims assessment  
Of the 16 articles reviewed: 
 
• 14 of the 16 papers presented a modeled cost-per-
QALY analysis 17 19 20 21 22 23 24 25 26 27 28 29 30 31   
• 9 of the 14 cost-per-QALY papers presented lifetime 
modeled claims 19 20 22 23 24 25 26 27 28 29  
• One paper presented the analysis as lives saved and 
costs 16 
• One paper presented results as costs per major 
complication/death avoided 18 
• Six papers were supported or funded by 
manufacturers and all modeled claims  supported 
the manufacturers’ product19 25 28 29 30 31 
 
Lifetime modeled cost per-QALY claims were not expected to 
generate evaluable claims. The only exception was the 
analysis by Carlson et al of the cost-effectiveness of 
tocilizumab versus adalimumab for patients with rheumatoid 
arthritis for whom methotrexate is inappropriate 29. In this 
case a six month initiation phase was modeled as well as the 
patient’s lifetime.  
 
Of the 5 cost-per-QALY models that did not take a lifetime 
perspective, the timeframes varied from 2 to 7 years. There 
was no suggestion in any of these papers as to how testable 
claims might be generated by the model and how these 
claims might be evaluated in a treating environment. The 
same conclusions apply to the remaining two papers. 
 
In respect of the four questions addressed above, the 
conclusions are: of the 16 economic evaluations presented in 
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2015 by Value in Health, only 7 (at most) had the potential to 
develop testable claims, although none did so. 
 
None of the economic evaluations addressed the issue of 
testable claims (and, of course, did not address the issue of 
how the claims might be evaluated and replicated) 
None of the evaluations cautioned readers as to the 
implications of generating non-testable claims as potential 
inputs to health care decisions 
 
Discussion 
Given the increased emphasis in the pharmacoeconomics 
literature on the potential role of QALYs as the preferred 
endpoint in cost-effectiveness claims, the fact that 14 of the 
16 economic evaluations utilized a cost-per-QALY framework 
should come as no surprise. Possibly more surprising is the 
fact that 9 of these 14 papers used a lifetime cost-per-QALY 
framework. Perhaps this can put be down to standards 
(including mandated and recommended guidelines for 
formulary submissions) for modeling the ‘natural’ course of a 
chronic disease. Even so, the framework and endpoints 
adopted puts these studies in the category of pseudoscience. 
The reader is asked to take (or leave) these conclusions at 
face value. It is unclear how these claims could be factored 
into formulary decisions if the recipient raised the issues of 
assessment and replication.  
 
Overall, however, the most interesting question that emerges 
from this review is the fact that none of the evaluations 
raised any concerns as to what is best described as the 
imaginary nature of the models presented. There is no 
attempt to address the issue of sufficient correspondence in 
constructing the model or simulation in generating predictive 
claims. Instead, the reader is asked to take the inherent 
reasonableness of the simulation or model at face value. With 
due regard to the limitations pointed to in these evaluations, 
the claims for cost-effectiveness, for the probable superiority 
of one product or course of treatment over another, the 
authors clearly believe that their models should be taken 
seriously as a quantitative contribution to informing health 
decision makers.  
 
This does not mean that, at least for a few of the evaluations 
presented, there is not the potential to generate testable 
predictions. The Vertuani et al study, for example, points out 
that QALYs as a measure of effectiveness may not fully 
represent the patient’s perspective 17. The authors note that 
as the QALYs were EQ-5D based, relatively small differences 
in pain may not be fully captured. In addition, the full 
treatment pathway after surgical complications was not 
modeled due to the absence of data, nor was there data to 
capture post-operative work loss. Even so, in focusing on a 
two year timeframe, it would have been possible to generate 
modeled claims and to propose how these might be validated 
in treatment settings, possibly including complementary 
measures of HRQoL as well as claims for resource utilization, 
reduction in length of hospital stay, reduced blood loss and 
fewer complications. This was not attempted.  
 
Another cost-per-QALY study that had the potential to 
generate testable claims over the short-term, is the Nguyen 
et al model of treatment resistant depression interventions19 
. The 3-year Markov model yields the unequivocal claim that 
rTMS dominated pharmacotherapy for patients with 
treatment resistant depression, generating (admittedly 
minimal) QALYs gained (1.25 vs. 1.18) but at a slightly lower 
cost with the 73% probability, at a threshold of A$50,000, 
that it is cost-effective. Given this it would surely have been 
possible to propose an assessment protocol that would have 
tested these claims, with possibility that with such minimal 
benefits and cost savings the claim for cost-effectiveness may 
have been overturned.  
 
The Legrand study, although based on an acute model of 
hemodynamic monitoring and fluid therapy strategies gave 
no indication of how this might be translated to evaluate 
claims for cost and clinical outcomes such as hospital 
mortality and major complications 18.  
 
Unfortunately, from the perspective (as discussed in detail 
below) of normal science, the preference for lifetime cost-
per-QALY models in 9 of the 16 papers points to the 
acceptance of a methodology that, while conforming to 
ISPOR recommended standards, is at odds with that of 
normal science. The models and claims are immune to failure 
and, as such, if these standards are accepted, should be put 
to one side. 19 20 22 23 24 26 27 28 29 . While there may be an 
audience for this type of model, there was no attempt to 
caution health decision makers that, even if the limitations to 
the model noted by the respective authors were overcome, 
the claims would still lack credibility and should be put to one 
side as speculative imaginary worlds. While they may appear 
persuasive in their simulation framework and the data 
sources utilized to populate the simulation, in the last resort 
we have no idea whether the claims made are right or even if 
they are wrong. Appeals to sensitivity analysis, the 
application of cost-effectiveness acceptability analysis to 
support thresholds and statements that there is an x% 
likelihood the product is cost-effective are simply speculation. 
They do nothing to change the fact that the claims are 
impossible to falsify or replicate. 
 
Indeed, what is missing in all of the models reviewed is any 
concept of feedback from claims, their replication and the 
potential for revising and enhancing models to accommodate 
new therapies as they enter the market place, competing 
against existing therapies.  
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There has been increasing concern expressed in the last few 
years over the presence of repetitive flaws and the need for 
guidelines to improve experimental reproducibility. This 
applies equally well to simulations and models in 
pharmacoeconomics. As noted in a recent editorial in Nature, 
applicants to the National Institutes of Health (NIH) are now 
required ‘to explain the scientific premise behind their 
proposals and defend the quality of their experimental 
design’ 16. More recently, Camerer et al in their evaluation of 
laboratory experiments in economics find, of the 18 studies 
considered, an effect size in the same direction in only 11 
replications with on average a replicated effect size of 66% of 
the original17 . As the authors point out ‘the deepest trust in 
scientific knowledge comes from the ability to replicate 
empirical findings’, although rarely carried out in the social 
sciences. 
 
Informing Decision Makers 
If these models and their claims are intended to inform 
decision makers, as presumably is the case for those 
sponsored by manufacturers, then the effort is probably 
wasted. In each case we could, presumably, engage other 
research groups to develop competing models and come up 
with competing claims. This possibility was recognized over 
20 years ago by the New England Journal of Medicine (NEJM) 
when the journal set out, in an Editorial, its policy on cost-
effectiveness studies 18.   The case put forward was that 
because of the discretionary nature of cost-effectiveness 
methods it was incumbent upon authors, journal editors and 
funders of such studies to minimize any source of bias. In 
consequence, the policy of the NEJM on publication was (and 
remains) not only to ask for an author’s financial connections 
with a company, but to reject for consideration any article, to 
include reviews and editorials, in which an author has a 
personal financial conflict of interest. In the present case, as 
noted above, 6 of the 16 papers had funding or other support 
from the manufacturer whose product, on the modeled 
assessment, was claimed to be cost-effective. 
 
There is, however, a more substantive reason than the 
potential for bias for journals such as the NEJM  to establish 
standards in accepting cost-effectiveness studies: the fact 
that simulated or modeled claims for cost-effectiveness, 
unless they generate testable hypotheses and meet the 
standards for normal science are simply imaginary worlds or 
thought experiments. As discussed below: simulations, even 
if there is a claim for similarity, are not experiments. Unless 
there is the ability to generate testable claims (and 
repeatedly test those claims) and provide guidance as to how 
these claims could be assessed, the cost-effectiveness 
analysis lacks credibility. The analysis may be aimed at 
informing and influencing decision makers but there is no 
way of judging whether the information provided is relevant 
to decision making. The claim may be quite misleading, 
indeed harmful, although we have no idea as to how 
misleading it might be.  
 
Testable Hypotheses 
The requirement for testable hypotheses in product and 
device impacts is unexceptional. Since the 17th century it has 
been accepted that if a research agenda is to advance, if 
there is to be an accretion of knowledge and if models are to 
generate meaningful hypotheses, then these hypotheses 
must be such that they can be empirically evaluated. This 
position is made abundantly clear by Wootton in his 
reassessment of the use of language in the idea of the 
scientific revolution in The Invention of Science 19 and by 
Grayling in his assessment of the intellectual history of the 
17th century The Age of Genius 20. 
 
If a simulation or model fails to generate testable or 
measurable hypotheses, then it should be seen as simply a 
construct to support the exploration of imaginary worlds or 
thought experiments and not part of a meaningful research 
program; a program that underpins the notion of progress in 
the accumulation of knowledge. Both Wootton and Grayling 
point to the motto of the Royal Society, first meeting in 1660 
and a Royal Charter in 1662, nullius in verba as evidence of 
the commitment to experimentation, falsification and 
replication, with Grayling, to give a wider European 
perspective, pointing to the motto of the Accademia del 
Cimento in Florence in 1657 and their motto Provando e 
Riprovando 27 28. Indeed, even earlier, as Wootton points out, 
in the 16th century Leonardo da Vinci (1452 – 1519) in notes 
prepared posthumously in 1540 for his Treatise on Painting 
(published in 1641) clearly anticipated the standards for the 
scientific method in rejecting ‘sciences which begin and end 
in the mind’ and which fail the ‘test of experience’27. 
 
In the early 20th century standards for empirical assessment 
were put on a sound methodological basis by Popper in his 
advocacy of a process of ‘conjecture and refutation’21 22 .  
Hypotheses or claims must be capable of falsification; indeed 
they should be framed in such a way that makes falsification 
likely. Life becomes more interesting if claims are falsified 
because this forces us to reconsider our models and the 
assumptions built into those models. To the extent that the 
proponents of the pharmacoeconomic modeled claim believe 
that it can be defended on the grounds that it ‘reflects reality’ 
or is a ‘reasonable representation’ of what is ‘out there’ 
(whatever those terms actually mean), it is worth reflecting 
on Popper’s statement: ‘never in science are inferences 
drawn from mere observational experience to the prediction 
of future events’ 23. The fundamental issue is one of 
demarcation: to distinguish science (e.g., natural selection) 
from pseudoscience (e.g., intelligent design).   
 
 
Commentary FORMULARY EVALUATIONS 
 
http://z.umn.edu/INNOVATIONS                      2016, Vol. 7, No. 2, Article 18                          INNOVATIONS in pharmacy   5 
 
Standards in Pharmacoeconomics 
It is curious that in the standards proposed by the 
International Society for Pharmacoeconomics and Outcomes 
Research (ISPOR) there is no mention of the need to meet the 
standards of normal, experimental science in respect of (i) 
falsification and (ii) replication. Certainly predictive validation 
(rather than falsification) is mentioned, but it is considered as 
more of an optional (and even preferred) extra to other 
recommended forms of model validation. The possibility of 
committing to an ongoing process of replication and 
assessing the presence of false positives is entirely absent. A 
reasonable question to ask is why this has this occurred? 
 
Looking back over the past 20 years there are literally 
hundreds (if not thousands) of published simulated and 
modeled claims that fail to meet the standards of normal 
science. A reviewer might then reasonably ask how did this 
situation arise? Is it an accident? Do we assume that those 
accepting these standards (and the number of ISPOR 
standards that support such models) were simply unaware of 
the standards of normal science? Or is there an implicit (if not 
explicit) acceptance that in pharmacoeconomics different 
standards should apply? Is there a research program, as it 
would be understood in the physical sciences, that underpins 
pharmacoeconomic studies? Or is pharmacoeconomics 
willing to continue to support the creation of imaginary 
worlds with studies that are immune to falsification? 
 
A curious feature of the pharmacoeconomics literature is the 
apparent absence, after some 30 years, of successor studies 
that have attempted to evaluate claims put forward in 
published modeled claims. Unlike disciplines like physics 
where there is an ongoing appraisal of claims and an 
accumulation of theoretical and empirical knowledge 
generated by practitioner’s ability to develop practical and 
useful models, pharmacoeconomics is silent.  
 
From the late 1980s when attention began to be given to the 
applications of decision modeling to clinical decision making, 
the role of decision models was seen as ‘informing’ health 
care decision makers. It was not clear, however, as to what 
form this provision of information should take and the 
standards by which this evidence should be judged. 
Weinstein and Fineberg in their seminal textbook on decision 
analysis argue that decision analysis ‘offers a prescriptive 
model for clinical decision making ….an aid, not a substitute 
for clinical reasoning’ 24. More recently Drummond et al in 
the 3rd edition of their text on economic evaluation see the 
‘ultimate purpose of economic evaluation is  …to inform 
different types of decision makers about the efficient 
allocation of health care resources’ with the ‘greatest use of 
these methods is to inform particular decisions in specific 
jurisdictions providing the means of bringing evidence from a 
range of sources together… and providing a framework for 
decision-making under uncertainty’ 25. Unfortunately, if 
‘information’ as an aid to decision making is presented either 
in the form of untestable hypotheses or where it is immune 
to falsification (and replication) it is difficult to see whether a 
decision maker should take the evidence presented seriously.  
 
Truth is Consensus 
But we do not have to subscribe to the standards of normal 
science; pharmacoeconomics is perfectly within its rights to 
adopt a relativist position where all perspectives are equally 
valid. Indeed, support for a relativist position is widespread, 
at least outside of the natural sciences. Following from the 
publication of Philosophical Investigation by Wittgenstein, 
and the view that truth is merely consensus, the emergence 
of the so-called Science and Technology Studies in the 1960s 
in the UK, as described by Wootton, in their advocacy of the 
equivalence principle saw a widespread acceptance of the 
relativist position 26 24. Applying the principle of symmetry, 
for relativists the content of science is to be understood 
sociologically. Relativists reject the notion that one body of 
evidence is superior to another. We cannot adopt the 
viewpoint of one community and reject another. As Wootton 
summarizes the relativist position: The success of a scientific 
research programme thus depends not on its ability to 
generate new knowledge but on its ability to mobilize the 
support of a community 24 . In this community research 
program evidence is always constructed; it is never 
discovered. Rather than attempting to come to grips with 
reality, science is about rhetoric, persuasion and authority.   
 
The embrace of a relativist position in pharmacoeconomics 
sets the stage for the acceptance of simulations to construct 
new evidence. Truth is constructed. Hypothesis testing and 
replication are redundant. Even, presumably, if the 
predictions relate to the lifetime discounted cost-per-QALY 
outcomes of a target chronic disease population. We put to 
one side the possibility that simulations can fail and accept 
that any simulation is ‘doomed to succeed’ 27.  
 
If decision makers are prepared to accept the relativist 
position then, presumably, this is the end of the story. 
Journals will continue to publish claims that are non-testable 
and immune to falsification, claims that are factored into 
formulary and pricing decisions. It is difficult to believe that 
this position is acceptable. It is difficult to take seriously a 
consensus belief that models and simulations are sufficiently 
representative of a target reality.  
 
An imaginary world yields imaginary claims. A consideration 
that needs to be kept in mind when a simulated or modeled 
claim is published that is sponsored by and which favors a 
manufacturer’s product or if recommendations are made by 
independent assessors. If a claim is immune to falsification 
then decisions for formulary listing, discounted or premium 
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pricing are open to challenge. A formulary committee cannot 
point to evidence, other than the constructed evidence of a 
simulation, to support their decision. Indeed, it is all too easy, 
given the inherent flexibility allowed in constructing 
imaginary worlds, for competitors to present contradictory 
claims. How could this existential threat be handled within a 
relativist paradigm?  With two imaginary worlds competing 
for attention, both with untestable competing claims, there is 
no basis for a resolution. The protagonists could argue over 
modeling techniques, over assumptions and over thresholds 
– a debate that is unlikely to lead anywhere. Even if ISPOR or 
some other organization took it upon itself the task of 
‘simulation adjudication’ it would seem a pointless exercise 
when testable short-term modeled competing claims could 
be readily adjudicated by an appeal to the facts: to 
falsification and replication.  
 
Attempts in the US attempts to assess comparative QALY 
product performance has, more by accident than an appeal 
to the standards of normal science, met resistance with the 
Patient Protection and Affordable Care Act (2010). The act 
forbids the Patient-Centered Outcomes Research Institute 
(PCORI) to use cost-per-QALY “or similar measure that 
discounts the value of a life because of an individual’s 
disability as a threshold to establish what type of health care 
is cost effective or recommended”. The fact that there 
appears to be little interest, in any case, by health care 
systems in the US in claims expressed in terms of QALYs, is a 
further positive feature. Indeed, from a global perspective, 
the US is not alone in failing to put procedures in place to 
collect QALYs on a regular basis – even if a QALY standard 
could be agreed as a common metric across health care 
systems. Even in the UK, where the reference case is the 
assessment standard, the fact is that no health authority 
collects QALYs. Given the absence of any acceptance and 
implementation of a QALY metric, the emphasis on QALY 
modeled claims seems even more difficult to defend. 
 
Conclusions 
Unfortunately, practitioners, journal editors and groups such 
as ISPOR do not have the luxury of putting the question of 
scientific credibility to one side. It may be a difficult decision 
to make particularly when it is pointed out that there are 
(and have been) substantial commitments made by 
manufacturers and others to supporting cost-effectiveness 
studies which in retrospect generate claims that are immune 
to failure. If we consider the resources manufacturers have 
devoted internally in staffing health technology assessment 
groups and to supporting consultant activities, the question 
may reasonably be asked as to what benefits have been 
derived from these activities and, for the future, what 
benefits might be expected if there are concerns as to the 
robustness and credibility of these activities? Should they 
continue to accept that decisions in medicine can be based 
on modeled or simulated claims that are untestable and 
which fail to meet the standards of normal science? 
 
What are the options open to ISPOR, Value in Health and to 
practitioners in pharmacoeconomics if they are to avoid the 
charge that all too often modeled claims lack credibility and 
fail to provide an input to health decision makers that is 
practical and useful? An important step would be to 
acknowledge that, for the past 25 years, those advocating 
standards and good practice for modeled claims have failed 
to consider the need to meet the standards of normal 
science. This may be a difficult decision to take; after all, to 
admit that literally dozens if not hundreds of published 
studies lack credibility and should be put to one side is not an 
easy decision. The next important step would be to 
reconsider the standards for ‘good’ modeling or simulation 
and ensure that these recognize the essential place of 
falsification and replication. The Editor of Value in Health 
could request that when authors submit simulations or 
models that lack testable claims that they state explicitly that 
the study does not meet the standards of normal science. 
Authors should state (i) that the claims are not open to (a) 
falsification and (b) replication and (ii) that in the absence of 
experimentation the claims may be right but also that they 
may be wrong. 
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Table 1: Imaginary Worlds: Economic Evaluation Studies Value in Health January 2015 to November 2015 
 
Paper 
(author) 
Target Population 
and Intervention 
Sponsor 
(if any) 
Modeling Technique and Claims Status Claims Assessment 
and Credibility 
Danese et 
al.28 
Breast cancer life 
years saved by 
trastuzumab plus 
chemotherapy alone 
as first line therapy 
vs. trastuzumab plus 
pertuzumab plus 
chemotherapy  
Genentech  Simulated life years saved from using 
trastuzumab as first line therapy in HER2+ 
metastatic breast cancer compared to 
counterfactual scenario without trastuzumab 
(which was approved in 1998) for period 
1999-2013 and projected life years to be 
saved from using trastuzumab and 
pertuzumab as first line therapy with 
chemotherapy in period 2013 to 2027 
compared to trastuzumab plus chemotherapy. 
From estimates of life years saved an example 
calculation of the value of trastuzumab and 
the combination of trastuzumab and 
pertuzumab at a population level at a value of 
$150,000 per life-year-saved. Cumulative life 
years saved from 1999-2013 from first line 
trastuzumab use was 156,413 (if 100% 
utilization life years saved would have been 
281,948). Life years saved projected for 2013-
2027 with trastuzumab projected to be 
328,200. With addition of pertuzumab (100% 
utilization) life years saved increased to 
466,159. Incremental economic value of life 
years saved (for 2013) was estimated to be 
$1.66 billion for trastuzumab with 
chemotherapy and an additional $1.37 billion 
if pertuzumab had been added (in 2015 
dollars). In terms of mean times to 
progression the gain from adding pertuzumab 
is $0.06 billion. Results supported sponsor’s 
product pertuzumab.  
Claims made 
impossible to verify 
both for life years 
saved and for 
incremental 
economic value to 
support addition of 
pertuzumab to 
therapy. No 
indication given by 
authors as to how a 
health care system 
might evaluate 
survival or 
economic value 
benefits from 
addition of 
pertuzumab and 
increasing 
utilization of both 
products in HER2+.  
Vertuani et 
al.29 
Comparison of 
minimally invasive 
surgery (MIS) 
compared to open 
surgery (OS) for the 
treatment of 
degenerative lumbar 
spinal conditions 
using lumbar spinal 
fusion in UK and Italy 
Medtronic 
International 
A 2-year procedure-based cost-per-QALY 
model. with sensitivity analysis to identify key 
cost drivers in surgical procedures. 
Incremental cost effectiveness values 
calculated with post-operative health state 
measured as QALYs (EQ-5D) from Swedish 
source. MIS was estimated to be the 
dominant therapy with the more expensive 
MIS procedure offset by reduced costs of 
perioperative hospitalization and less 
complications. HRQoL significantly improved 2 
years post-operation for both techniques with 
0.72 QALYs for MIS and 0.68 QALYs for OS (a 
gain of 0.04 QALYs for MIS over OS).  
Calculated ICERs showed MIS to be the 
dominant therapy in both UK and Italy. ICERs 
were below recognized threshold values. 
Although an acute 
intervention the 
authors give no 
direction as to how 
a surgical unit or 
health care system 
might evaluate 
these claims. The 
claims (e.g., 
resource utilization, 
reduction in length 
of stay, reduced 
blood loss, fewer 
complications) are 
potentially testable 
but no guidance is 
given for possible 
evaluation, and 
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provision of 
feedback. 
Impossible to 
assess whether 
these claims would 
be supported in a 
treating 
environment. 
Legrand et 
al.30 
Comparison of three 
minimally invasive 
hemodynamic 
monitoring and fluid 
therapy strategies in 
intermediate and 
high risk abdominal 
surgery applications: 
APPWA (arterial 
pulse pressure 
waveform analysis); 
CCA (conventional 
clinical assessment; 
and ED (esophageal 
Doppler).   
None Decision model with three possible outcomes: 
discharge without death or complications, 
major complications and death. Outcomes 
based on meta-analysis of RCTs. ICERs 
calculated for costs per major complication 
avoided and cost per death avoided. One way 
sensitivity analysis and probabilistic sensitivity 
analysis performed with results presented as 
cost-effectiveness acceptability curves. In 
one-way sensitivity analysis APPWA was 
always dominant compared to CCA and ED 
dominant in most scenarios. ED was dominant 
over APPWA in three situations, but was 
dominated in all others. In the probabilistic 
sensitivity analysis APPWA wand AD were 
dominant compared to CCA in 97.3% and 
76.1% of cases and were in 0% and 13.3% of 
cases respectively. ED compared to APPWA 
was dominant in only 23.8% of cases and 
dominated in 76.1% of cases. In deaths 
avoided, the probabilistic sensitivity analysis 
showed that APPWA and ED dominated CCA 
in 92.9% and 69.5% of cases respectively. ED 
compared to APPWA was dominant in 20.8% 
cases and dominated by APPWA in 27.6% of 
cases. 
 
Although an acute 
intervention the 
authors give no 
indication as to 
how a surgical unit 
or health system 
might evaluate the 
short term claims 
for cost and clinical 
outcomes (hospital 
mortality, major 
complications) to 
choose between 
APPWA and ED. As 
the threshold 
values for the 
probabilistic 
sensitivity analysis 
are unlikely to 
mean anything to 
decision makers, 
they add nothing to 
the analysis. There 
is no guidance for 
possible evaluation, 
and provision of 
feedback.  
Nguyen & 
Gordon31 
Comparison of 
repetitive 
transcranial 
magnetic simulation 
(rTMS) versus 
antidepressant 
pharmacotherapy in 
treatment resistant 
depression 
Griffith 
University 
assessment 
group 
contracted 
to the 
Australian 
Government 
Hypothetical 3-year health state transition 
(Markov) model with key outcome 
incremental cost per QALY, the additional cost 
of rTMS over additional QALY compared to 
antidepressants; both discounted at 5%. 
QALYs gained were greater with rTMS while 
costs were slightly lower. At a threshold of 
A$50,000 per QALY the probability that rTMS 
was dominant was 32% and likelihood it was 
cost-effective was 41%. Resources and costs 
were standardized to meet constraints of 
Markov cycle. 
There is no 
guidance for 
possible evaluation, 
and provision of 
feedback. Unclear, 
for example, how 
QALY claims would 
be assessed. 
Impossible to 
assess whether 
these claims would 
be supported in a 
treating 
environment. No 
support given for 
A$50,000 threshold 
and how treatment 
centers should or 
would interpret the 
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claims for 
dominance and 
cost-effectiveness. 
Collins & 
Schwemm32 
Comparison of 
vancomycin versus 
linezolid 
None Cost per QALY decision model, building on 
previous ZERHyR cost-effectiveness models, in 
a hypothetical patient cohort with a lifetime 
horizon. Primary outcome measure 
incremental cost per QALY gained in a 
probabilistic sensitivity analysis driven by a 
Monte Carlo simulation. Base case analysis 
showed linezolid patients experienced a 6% 
cost increase while gaining a 0.15 QALY 
increase. Results of the sensitivity analysis 
showed that linezolid 78% cost effective at 
$100,000 US threshold and in range 72.1% to 
79.7% if threshold varied between $50,000 
and $150,000. Vancomycin dominated in 
population with documented MRSA. 
The lifetime 
framework for this 
model excludes any 
possibility of 
establishing 
testable claims. 
There is no 
guidance for 
possible evaluation, 
in particular given 
the acknowledged 
variability in the 
modeled results, 
and no provision 
for feedback for 
health centers 
evaluating the 
relative coast-
effectiveness 
claims for the 
treatment options.  
Ting et al.33 Comparative cost-
effectiveness 
analysis of erlotnib, 
afatinib and 
cisplatin-pemetrexed 
for first line 
treatment of 
epithelial growth 
factor receptor 
mutation-positive 
non-small-cell lung 
cancer in the US  
None Lifetime Markov model with cycle length of 
one month using Monte Carlo simulation. 
Cohort simulated until all patients were dead. 
Primary outcomes cost and QALYs. UICER 
ratios ranked treatments. A cost-effective 
treatment was defined as an ICER < $100,000 
per QALY. Uncertainty captured through cost-
effectiveness acceptability curve. Base case 
found erlotnib cost effective compared to 
options at threshold of $100.000 QALY in 75% 
to 80% of model iterations. Expected value of 
information (EVPI) techniques applied to 
identify cost of research to reduce parameter 
uncertainty for effective lifetime of 
treatments. 
There is a potential 
for testable 
predictions given 
the short 
survivorship among 
patients. The 
lifetime framework 
for this model 
excludes any 
possibility of 
establishing 
testable claims. 
There is no 
guidance for 
possible evaluation, 
and provision of 
feedback for health 
centers evaluating 
the relative cost-
effectiveness 
claims for the 
treatment options.  
Nazir et al.34 Overactive bladder 
Mirabegron vs 
antimuscarine 
agents 
Astellas 
Pharma 
 
Cost per QALY Markov model with a one-
month cycle over a 5 year time horizon. 
Patients were distributed across 25 symptom 
severity profiles (from the SCORPIO trial) and 
assigned at entry to either therapy. 
Transitional probabilities estimated from 
multinomial logic regression model. In 
absence of data, assumed 90% of patients 
Authors claimed 
that from UK 
perspective the 
sponsor’s product 
was cost-effective 
compared to 
antimuscarine 
agents. Given the 
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experiencing adverse events would 
discontinue. Utility values (EQ-5D) varied by 
symptom severity and were estimated by 
regression modeling from reported trial 
symptoms. Discount rate of 3.5% applied to 
costs and health benefits. Primary output ICER 
expressed as cost per QALY gained. Results 
supported sponsors product with ICERs in 
range £367 to £15,593 QALY gained, below 
threshold of £20,000 
short time frame 
for the model there 
is a potential for 
developing testable 
predictions. 
However, there 
were no testable 
claims presented or 
guidance as to how 
the claims made 
might be 
evaluated. As the 
claims are 
presented in cost-
per-QALY terms 
with QALYs 
estimated by 
regression model, 
no guidance was 
given as to how 
QALYs might be 
generated for 
treating 
populations. There 
is no guidance for 
possible evaluation, 
and provision of 
feedback for health 
centers evaluating 
the cost-
effectiveness claim 
for the treatment 
options. 
Bermingham 
et al.35 
Assessment of seven 
alternative antiviral 
strategies HBeAg-
positive or HBeAg-
negative hepatitis B 
Funding 
from 
National 
Institute for 
Care and 
Clinical 
Excellence 
(NICE) to 
National 
Care 
Guideline 
Centre 
Probabilistic Markov cohort model to 
estimate lifetime costs and QALYs of 
competing therapies. UK NHS and personal 
social services perspective. Costs and QALYs 
discounted at 3.5%. Entry to model via either 
HBeAg-positive or HBeAg-negative hepatitis B. 
Average age at start of treatment 31 and 40 
years respectively. Nineteen relevant 
treatment sequences were tracked. Model 
claimed peg-IFN ɑ-2a most effective first line 
antiviral. For those with  HBeAg-positive and 
HBeAg-negative CHB failing to achieve 
seroconversion or viral suppression the 
sequence peg-IFN ɑ-2a →TDF → TDF + LAM 
most effectives with cost of £7,488 per QALY 
gained compared to no treatment. For those 
with HBeAg-negative CHB peg-IFN ɑ-2a→ETV 
→TDF is most effective treatmnent with cost 
of £6,981 per QALY gained. Authors 
recognized that model limited by lack of long 
term evidence of efficacy, resistance and off-
As a lifetime cost-
per-QALY model, 
the claims are 
impossible to 
evaluate. No 
attempts were 
made by the 
authors to 
generate short-
term testable 
claims even though 
they acknowledged 
that long term data 
to support 
modeling was 
sparse or non-
existent. There is 
no guidance for 
possible evaluation, 
and provision of 
feedback for health 
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treatment durability, and only a few trials that 
have evaluated effectiveness of sequential 
treatment therapies in patients developing 
resistance, effectiveness and safety of 
antiviral combinations and on treatment rates 
of seroconversion.  
centers evaluating 
the cost-
effectiveness 
claims for the 
various treatment 
options and 
sequences. 
Dhankar et 
al.36 
To assess population 
level impact and 
cost-effectiveness of 
hepatitis A 
vaccination 
programs in the US 
Merck Sharp 
& Dohme 
Corp 
Modeled universal vs. regional childhood 
lifetime hepatitis A vaccination deterministic, 
age-structured epidemiologic model with an 
equilibrium age distribution and a stationary 
population to evaluate transmission of and 
vaccination against HAV infection in the US. 
Population for the model was divided in 
distinct classes (maternal antibodies, 
susceptible, exposed etc.) with each 
component further categorized into 110 age 
groups. Direct treatment costs and indirect 
costs (work loss) included, as well as public 
health disease control costs. QALYS were 
assumed with discounted weight of 0.68 for 
all outcomes except liver transplant which had 
a weight of 0.73. In all other health states 
weight was unity. Outcomes were incidence 
of hepatitis and cost and QALYS over 100 
years. Probabilistic sensitivity analysis 
indicated that universal vaccination less costly 
and more effective that regional vaccination 
in all simulations.  
As a lifetime cost-
per-QALY model, 
the claims are 
impossible to 
evaluate. No 
attempts were 
made by the 
authors to 
generate short-
term testable 
claims (e.g., 
complications from 
vaccine).  There is 
no guidance for 
possible evaluation, 
and provision of 
feedback for 
policymakers who 
might initiate a 
universal 
vaccination 
program.  
de Waure et 
al.37 
Comparison of cost-
effectiveness and 
budget impact of 
Therakos online 
extracorporeal 
photopheresis (ECP) 
to commonly used 
alternatives 
(mycophenolate, 
pentostatin, 
imatinib) for 
management of 
steroid-
refractory/resistant 
chronic graft versus-
host-disease (cGvHD) 
in Italy. 
Therakos Inc  A Markov model with a 7-year time frame and 
applied via a Monte Carlo simulation to a 
hypothetical cohort of 1000 patients. The 
model captured 3 health states: complete 
response, partial response and stable disease. 
The model cycle was 3 months. Health state 
utilities were derived from the literature with 
estimated direct medical costs. A discount 
rate of 3% was applied to costs and QALYs. 
The economic evaluation supported the 
dominance of Therakos online (ECP) 
generating lower costs and higher QALY gains. 
The probability sensitivity analysis supported 
this conclusion. The results supported the 
sponsor’s product. 
There was the 
potential, given the 
number of 
outcome measures 
(to include QALYs) 
to have proposed a 
set of testable 
propositions; 
evaluable well 
within the 7 year 
model timeframe. 
No attempts were 
made by the 
authors to 
generate short-
term testable 
claims.  There is no 
guidance for 
possible evaluation, 
and provision of 
feedback for 
policymakers who 
might initiate the 
proposed 
treatment 
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sequence. 
Linssen et 
al.38 
To evaluate the cost-
effectiveness of 
screening 50 to 70 
year adults for 
hearing loss in the 
Netherlands 
comparing no 
screening, telephone 
screening, internet 
screening, screening 
with a handheld 
device and 
audiometric 
screening. 
Partial 
funding by 
the Heinsius 
Houbolt 
Foundation 
A lifetime Markov model to evaluate cost-
effectiveness of screening from a health care 
perspective. A cost-per-QALY model that 
simulated no intervention against four types 
of nationwide screening: telephone, internet, 
Hearcheck and audiometric screening (both 
with general practitioner). A total of 76 
screening strategies considered in model and 
compared to no intervention. Utilities assed 
via HUI Mark 3 instrument questionnaire to 
generate age-dependent utility scores. Costs 
and effects discounted at 4% and 1.5% 
respectively. Probabilistic sensitivity analysis 
yielded cost-per-QALY screening strategies 
less than €20,000 /QALY. Telephone and 
internet strategies dominated. Telephone 
strategies were either dominated or 
extendedly dominated by internet screening 
strategies. 
 
As a lifetime cost-
per-QALY model, 
the claims are 
impossible to 
evaluate. No 
attempts were 
made by the 
authors to 
generate short-
term testable 
claims.  There is no 
guidance for 
possible evaluation, 
and provision of 
feedback for 
policymakers who 
might initiate an 
internet screening 
program (as 
compared, for 
example, to a 
telephone 
screening 
program). 
Visser et al.39  Cost-effectiveness of 
cognitive behavioral 
group training versus 
wait-list control for 
patients with 
unexplained physical 
symptoms (UPS: 
DSM-IV somatoform 
disorder).  
None A probabilistic Markov model with three 
health states: poor health, average health; 
death based on SF-36 PCS summary score. 
Model utilized 3 month cycles over a four year 
period. Assessment in cost per QALY. Data 
from UPS randomized trial (n = 162).  After 4 
years group training dominant with 0.06 
QALYs gained and €828 reduction in costs. 
Cost-effectiveness improved with time 
achieving threshold €30,000 QALY at 18 
months and group cost saving after 33 
months.  
Although a 
relatively short 
time frame no 
attempts were 
made by the 
authors to 
generate short-
term testable 
claims.  There is no 
guidance for 
possible evaluation, 
and provision of 
feedback for 
policymakers who 
might initiate the 
group training. 
Simons et 
al.40 
Assessment of 
patient outcomes 
and cost-
effectiveness of 
redesign of care 
processes in patients 
with head and neck 
cancer. 
None Markov lifetime model utilized to evaluate 
biopsy process of suspicious lesions under 
local instead of general anesthesia, and 
combining computed tomography and 
positron emission tomography for diagnostics 
and radiotherapy planning. Patients in model 
stratified by disease location and stage (8 
groups). Costs and QALY (EQ-5D) estimates 
calculated for each tumor site. Different gains 
in waiting time were realized for each patient 
group. New care process cost-effective for all 
studied treatment sites (using thresholds of 
both €80,000 and €20,000 QALY. 
As a lifetime cost-
per-QALY model, 
the claims are 
impossible to 
evaluate. No 
attempts were 
made by the 
authors to 
generate short-
term testable 
claims.  There is no 
guidance for 
possible evaluation, 
Commentary FORMULARY EVALUATIONS 
 
http://z.umn.edu/INNOVATIONS                      2016, Vol. 7, No. 2, Article 18                          INNOVATIONS in pharmacy   13 
 
and provision of 
feedback for 
policymakers as a 
national policy, or 
health centers who 
might initiate a 
new care product 
in different 
treatment settings. 
Liu et al.41 Cost-effectiveness of 
high dose 
hemodialysis (HD) 
versus conventional 
in center HD (ICHD) 
over a lifetime 
horizon from a UK 
payer’s perspective.  
Baxter 
Healthcare 
Corp 
Markov cost per QALY model comparing HD 
with conventional ICHD with current and 
hypothetical HD reimbursement tariffs. 
Outcome cost-per-QALY over lifetime of 
patient cohort. High dose HD in-center 
associated with higher costs and QALYs  versis 
conventional ICHD and thus not cost effective 
at UK thresholds. HD at home associated with 
lower costs and QALY increase compared to 
ICHD. High-dose HD potential to offer 
improved clinical and QALY outcomes over 
conventional ICHD, under current UK 
payments policy, considered cost-effective if 
conducted at home (61.8% at £20,000 and 
83.7% at £30,000). High-dose HD is the 
sponsor’s product.  
  
As a lifetime cost-
per-QALY model, 
the claims are 
impossible to 
evaluate. No 
attempts were 
made by the 
authors to 
generate short-
term testable 
claims.  There is no 
guidance for 
possible evaluation, 
and provision of 
feedback for 
policymakers as a 
national policy, for 
at home versus in-
center HD 
hemodialysis under 
alternative 
reimbursement 
schemes.  
Carlson et 
al.42 
Cost-effectiveness of 
tocilizumab (TCZ) 
monotherapy versus 
adalimumab (ADA) in 
persons with 
rheumatoid arthritis 
for whom 
methotrexate is 
inappropriate. 
Genentech 
Inc. 
Cost-effectiveness of TCZ versus ADA assessed 
over two time horizons: The treatment 
initiation phase of 6 months and the patient 
lifetime. The latter timeframe utilized a 
patient level simulation model to estimate 
incremental cost per QALY.  EQ-5D scores 
were mapped from the HAQ scores. One-way 
and probabilistic sensitivity simulation was 
used to capture uncertainty. In the 6 month 
model TCZ cost more than ADA with the ICER 
ranging from $6,570 per additional 
achievement of LDAS to $14,265 per 
additional ACR70 response. In the lifetime 
model, the incremental QALY gain of 0.04 life 
years and 0.23 QALYs while increasing cost by 
$8,532. This produced an ICER of 
$36,944/QALY for TCZ compared to ADA. The 
results of the probabilistic sensitivity analysis 
demonstrated that there is more than 50% 
probability that TCZ is cost-effective 
compared to ADA mono if threshold is 
$40,000/QALY. The probability that TCZ is 
While there is a 
potential for 
generating 
evaluable claims 
from the 6 month 
model, this was not 
explored. As a 
lifetime cost-per-
QALY model, the 
claims are 
impossible to 
evaluate. There is 
no guidance for 
possible evaluation, 
and provision of 
feedback for 
treatment centers. 
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cost-effective compared to ADA is 100% at all 
levels of willingness to pay. The authors 
concluded that ADA is cost-effective in this 
patient group. TCZ is the sponsor’s product. 
Chen et al.43 Cost-effectiveness of 
rituximab 
maintenance (MR) 
and 
radioimmunotherapy 
consolidation (RIT) 
versus observation in 
progression free 
survival following 
frontline therapy in 
follicular lymphoma 
(FL). 
Partial 
support by 
Spectrum 
Markov model lifetime cost and QALYs for the 
MR and RIT treatments compared to 
observation for those with advanced stage FL. 
Health states defined were: before first 
progression, first progression, second 
progression and death. Health utility 
estimates from the published literature. 
Primary analyses of effectiveness and costs 
were compared within each clinical trial. 
Compared to observation QALY gains for both 
MR and RIT were in the range 1.026 to 1.399. 
Incremental costs per QALY gained were in 
range $37,412 to $40,851.Both MR and RIT 
demonstrated favorable and similar cost 
effectiveness profiles.   
While there is a 
potential for 
generating 
evaluable claims 
from the trials (e.g., 
progression free 
survival) identified 
in the study this 
was not explored. 
As a lifetime cost-
per-QALY model, 
the claims are 
impossible to 
evaluate. There is 
no guidance for 
possible evaluation, 
and provision of 
feedback for 
treatment centers. 
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